Menu
Dr. Esmon is a pioneer in coagulation biology. He is a distinguished career scientist at the Oklahoma Medical Research Foundation (OMRF) and an Adjunct Professor in the Dept of Biochemistry, Molecular Biology and Pathology at the University of Oklahoma Health Sciences Center. A Howard Hughes Medical Institute (HHMI) investigator from 1988 to 2013, he is also an elected member of the National Academy of Sciences in 2002. In the early 1980s, Dr. Esmon discovered thrombomodulin which switches the physiological function of thrombin from procoagulant to anticoagulant, resulting in accelerated protein C activation on endothelium. His previous discoveries have resulted in two drugs that have received approval from the FDA. Dr. Esmon has published more than 300 publications related to mechanisms that control the process of blood clotting and the links between the controls of blood clotting and inflammation. He has served as a consultant with numerous large and small pharmaceutical companies and institutions. Dr Esmon is an inventor of the patent technology monoclonal antibodies against activated protein C.
Dr. Ginsburg is a James V. Neel Distinguished University Professor and Warner-Lambert/Parke-Davis Professor, Department of Internal Medicine, Human Genetics and Pediatrics, University of Michigan Medical School. He is a elected member of the National Academy of Medicine and the National Academy of Sciences. Dr. Ginsburg has dedicated his career to understanding the components of the blood clotting system and how disturbances in their function lead to human bleeding and blood-clotting disorders, including Hemophilia, Factors V and VIII combined deficiency, von Willebrand disease, and thrombotic thrombocytopenia purpura. He has published more than 230 original articles and served as a consultant for several biotech and pharmaceutical companies.
Dr. Pipe is a Professor and the Laurence A. Boxer Research Professor of Pediatrics and Professor of Pathology at the University of Michigan, Ann Arbor. He is the medical director of the Pediatric Hemophilia and Coagulation Disorders Program and medical director of the Special Coagulation Laboratory. His clinical interests include bleeding and thrombotic disorders and congenital vascular anomalies. Dr. Pipe is a clinical leader in novel therapeutics for hemophilia clinical trials and also directs a basic research lab investigating coagulation factor VIII and the molecular mechanisms of hemophilia A. He has served as Chair of the Board of Directors for the American Thrombosis and Hemostasis Network and most recently as Chair of the Medical and Scientific Advisory Committee to the National Bleeding Disorders Foundation (NBDF).
Dr. Xia is a Professor and Chair of the Cardiovascular Biology Research Program at the Oklahoma Medical Research Foundation (OMRF), and Merrick Foundation Chair in Medical Research at OMRF. Dr. Xia’s research has focused on key pathways to uncover molecular mechanisms on vascular integrity, thrombosis, platelet biology, and rare genetic disorders, including hemophilia and thrombotic thrombocytopenic purpura. He has published many original research articles in top ranked biomedical journals, such as Nature, Science, Blood, Circulation, and others. Dr. Xia is currently the Vice Chair and Chair-Elect of the Scientific Committee on Megakaryocytes and Platelets for the American Society of Hematology.
